Skip to content
OpenCapital
Get started

Ionis Pharmaceuticals IONS Cash Provided by (Used in) Operating Activity, Including Discontinued Operation

Cash Provided by (Used in) Operating Activity, Including Discontinued Operation at other companies

Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$408.2M-5.0%
Pfizer logo
PfizerPFE
——
ALN
Alnylam PharmaceuticalsALNY
——
Roivant Sciences logo
Roivant SciencesROIV
——
Royalty Pharma logo
Royalty PharmaRPRX
——
Amgen logo
AmgenAMGN
——

Other financials

Income statement

See full
Revenue$246.1M+87.0%
Gross profit$243.1M+86.8%
Operating income-$117.4M+20.0%
Net income-$92.5M+37.0%
EPS (diluted)-$0.56+39.8%

Balance sheet

See full
Cash & equivalents$173.4M-34.4%
Total debt$691.7M+334%
Total equity$491.4M+3.3%
Total assets$3.4B+22.6%

Cash flow

See full
Operating cash flow-$792.8M-426%
CapEx$21.8M+73.0%
Free cash flow-$814.6M-399%

Valuation

See full
Market cap$12.25B+159%
Enterprise value$12.77B+175%
P/S11.6×+5.0×

Profitability

See full
Gross margin98.4%-0.2pp
Operating margin-33.3%-11.0pp
Net margin-30.9%-10.5pp
FCF margin-77.4%+35.3pp

Returns & leverage

See full
Return on equity-67.6%-20.3pp
Debt / equity1.4×+1.1×
Current ratio4.1×-5.6×

Where this comes from

Reported directly by Ionis Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ionis Pharmaceuticals's cash provided by (used in) operating activity, including discontinued operation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ionis Pharmaceuticals's cash provided by (used in) operating activity, including discontinued operation?
Ionis Pharmaceuticals (IONS) reported cash provided by (used in) operating activity, including discontinued operation of -$792.82M in Q1 2026.
How has Ionis Pharmaceuticals's cash provided by (used in) operating activity, including discontinued operation changed year-over-year?
Ionis Pharmaceuticals's cash provided by (used in) operating activity, including discontinued operation decreased by 425.8% year-over-year, from -$150.78M to -$792.82M.
What is the long-term trend for Ionis Pharmaceuticals's cash provided by (used in) operating activity, including discontinued operation?
Over 4 years (2021 to 2025), Ionis Pharmaceuticals's cash provided by (used in) operating activity, including discontinued operation has grown at a 71.8% compound annual growth rate (CAGR), from $30.8M to -$268.58M.
What does cash provided by (used in) operating activity, including discontinued operation mean?
The net cash flow resulting from the company's primary business activities.
How do you interpret cash provided by (used in) operating activity, including discontinued operation?
Positive cash flow indicates the business can fund operations internally; negative cash flow suggests reliance on external financing or cash reserves.
How does cash provided by (used in) operating activity, including discontinued operation compare across companies?
A primary metric for assessing financial health across all industries.